{"id":"W4306724295","doi":"10.1200/jco.21.02947","title":"Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Novartis Institutes for BioMedical Research; EMD Serono; Genentech; Sierra Oncology; PharmaMar; Astellas Pharma; Eisai; G1 Therapeutics; National Institute of Environmental Health Sciences; MacroGenics; Silverback Therapeutics; INOVIO Pharmaceuticals; Cardinal Health; Puma Biotechnology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Agios Pharmaceuticals; Ipsen; Array BioPharma; Five Prime Therapeutics; Halozyme; Mirati Therapeutics; Clovis Oncology; Astex Pharmaceuticals; PTC Therapeutics; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Invitae; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Hazard ratio; PARP inhibitor; Oncology; Urology; Progression-free survival; Clinical endpoint; Randomized controlled trial; Cancer; Gastroenterology; Overall survival; Poly ADP ribose polymerase; Confidence interval","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007447253,0.000147715,0.001943331,0.0001080254,0.0001777882,0.0000135809,0.0002040248,0.00007563251,0.0001907263],"category_scores_gemma":[0.004207015,0.00006560229,0.0004446372,0.0002269385,0.0005867187,0.000118246,0.00004387819,0.0007396054,4.489733e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004102566,"about_ca_system_score_gemma":0.01528417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009935194,"about_ca_topic_score_gemma":0.001839004,"domain_scores_codex":[0.9950235,0.0009269883,0.002536683,0.0002239148,0.001066407,0.0002224588],"domain_scores_gemma":[0.9890518,0.006838981,0.00261086,0.0001480177,0.001174607,0.0001757434],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9837683,0.001202262,0.0003802398,0.0000341587,0.002420301,0.0001195918,0.0005071838,0.0006804765,0.0001345585,0.0001562116,0.003269473,0.007327239],"study_design_scores_gemma":[0.9290236,0.01747786,0.0005108135,0.0001049428,0.001575267,0.00003758199,0.0003772866,0.0006545924,0.0001310075,0.0007457127,0.04928174,0.00007963689],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9523882,0.001594356,0.0001132537,0.03623984,0.002893868,0.004702331,0.001256941,0.000008445305,0.0008027771],"genre_scores_gemma":[0.9895,0.002093617,0.002766629,0.0008601725,0.001578876,0.0008598447,0.00008068266,0.00002125535,0.002238934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05474475,"threshold_uncertainty_score":0.9902983,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2730445151668799,"score_gpt":0.5330496930102513,"score_spread":0.2600051778433713,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}